Current perspectives on the design of phase II trials of new drugs for the treatment of heart failure
Open Access
- 1 April 2000
- journal article
- research article
- Published by Elsevier in American Heart Journal
- Vol. 139 (4), S202-S206
- https://doi.org/10.1016/s0002-8703(00)90074-7
Abstract
No abstract availableThis publication has 19 references indexed in Scilit:
- Treatment of severe heart failure: quantity or quality of life? A trial of enoximone. Enoximone Investigators.Heart, 1994
- How should physicians view heart failure? The philosophical and physiological evolution of three conceptual models of the diseaseThe American Journal of Cardiology, 1993
- The neurohormonal hypothesis: A theory to explain the mechanism of disease progression in heart failureJournal of the American College of Cardiology, 1992
- The placebo effect in heart failureAmerican Heart Journal, 1990
- Vasodilator and inotropic drugs for the treatment of chronic heart failure: Distinguishing hype from hopeJournal of the American College of Cardiology, 1988
- Prevention and Reversal of Nitrate Tolerance in Patients with Congestive Heart FailureNew England Journal of Medicine, 1987
- Chronic renal and neurohumoral effects of the calcium entry blocker nisoldipine in patients with congestive heart failureJournal of the American College of Cardiology, 1987
- Minoxidil in patients with chronic left heart failure: contrasting hemodynamic and clinical effects in a controlled trial.Circulation, 1984
- Decreased Lymphocyte Beta-Adrenergic-Receptor Density in Patients with Heart Failure and Tolerance to the Beta-Adrenergic Agonist PirbuterolNew England Journal of Medicine, 1981
- Hemodynamic and clinical tachyphylaxis to prazosin-mediated afterload reduction in severe chronic congestive heart failure.Circulation, 1979